Mr Mrs Miss Ms Dr Other

Mr
Matthew
Johnson

Partner & Patent Attorney

Manchester Office Alderley Park Office

Chemistry

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 738 487 7684
Email. mjohnson@hgf.com
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.

Experience

Matthew has extensive experience relating to the pharmaceutical industry, having started his career in medicinal chemistry at GSK where he delivered small molecule development candidates for neurological indications, such as Alzheimer's Disease and neuropathic and inflammatory pain.

Matthew specializes in obtaining and defending rights relating to pharmaceutical subject matter including new chemical entities, crystal forms, synthetic processes, intermediates, formulations, combination products and medical uses. In addition to European patent drafting and prosecution, Matthew also manages the prosecution of patent portfolios worldwide, and also has experience of obtaining Supplementary Protection Certificates (SPCs) in many European countries.

He regularly provides advice to clients on EPO opposition and appeal strategy and has successfully defended and attacked patent rights covering various commercial products via the central opposition procedure at the EPO. Matthew also regularly assist his clients with due diligence activities associated with in-licencing, such as freedom-to-operate opinions.

Besides pharmaceuticals, Matthew regularly assists his clients obtain and defend patent rights in relation to agrochemicals, catalysis, polymers, cleantech and food science.

Qualifications

Patent Attorney

Chartered (UK)
Europe


MCHEM

Chemistry and Pharmacology

POSTGRADUATE DIPLOMA OR CERTIFICATE

Certificate in Intellectual Property Law

OTHER

Patent Attorney Litigator

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Read article
Event - 14th October 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Event details

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Read article

T 0792/24: Novelty and Inventiveness of Second Medical Use Claims

The EPO Board of Appeal’s decision in T 0792/24 provides helpful guidance on the assessment of novelty and inventive step for European second medical use claims. In light of a …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.